Patheon has announced the appointment of Steve Lam as senior vice president of the company’s biologics business. Lam will report to Lukas Utiger, president of the company’s Drug Substance Services (DSS) segment, effective immediately. Biologics is a fast-growing area of the industry, which requires experience and expertise because of their complexity.
For the past 18 years, Lam has served as vice president of operations for Amgen, one of the world's leading independent biotechnology companies. He led a company-wide transformation initiative driving robust quality management processes and operational excellence. He brings to Patheon more than 25 years of leadership experience in biopharmaceutical operations with a focus on manufacturing and commercializing human therapeutics. He has specific expertise in protein manufacturing, cGMP compliance, quality systems and technology transfer.
“Our biologics business is an area with tremendous growth potential for Patheon,” said Utiger. “With Steve’s experience and his broad client perspective, he will energize our efforts and support our biopharmaceutical clients who are looking for a knowledgeable partner with scale and expertise to meet their needs. He will help us to continue to pursue strategies that capitalize on this expanding area of our business.”
Lam’s experience includes responsibility for lean manufacturing transformation and driving efforts toward greater efficiency. His efforts to improve manufacturing strategy, reduce risk and enhance product quality resulted in increased revenue while providing Amgen with new capabilities.
Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.